DRG Epidemiology's coverage of acute myeloid leukemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
The number of incident cases of AML in the countries under study will increase by 43%, from 58,000 to 82,000, in ten years. Of the countries considered in this analysis, the incidence of AML is…
The number of incident cases of AML in the Asia-Pacific countries under study will increase by 36%, from 10,500 to 14,200, in ten years. Of the countries considered in this analysis, the…
The number of incident cases of AML in the countries under study will increase by 33%, from 3,866 to 5,116, in ten years. Of the countries considered in this analysis, the incidence of AML is…
Clarivate Epidemiology's coverage of chronic myeloid leukemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
The number of incident cases of AML in the countries under study will increase by 38%, from 3,150 to 4,300, in ten years. Of the countries considered in this analysis, the incidence of AML is…
The number of incident cases of AML in the European countries under study will increase by 18%, from 5,876 to 6,932, in ten years. Of the countries considered in this analysis, the incidence of…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Acute myeloid leukemia patient populations covering 171 countries…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 400 currently available and novel biosimilar products, detailing…
Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal…
MARKET OUTLOOK China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Only two targeted agents…
MARKET OUTLOOK NASH is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of diabetes and…
Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance,…
The market for prescription migraine therapies comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the…
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was…
